Abstract
We administered DAC-Tam therapy as a treatment of the progressive stage of melanoma in a patient on maintenance hemodialysis. The patient received an infusion of CDDP (50mg/m2) as the key drug in this treatment. We measured the plasma concentration of total platinum, and non-protein bound platinum of the patient. Measuring the pharmacokinetics of CDDP in serum, safe and sufficient concentration of CDDP ( 0.25μg/ml<free platinum) in this patient's serum was determined. As the size of the lung's metastatic tumors had not changed for one month after CDDP administration, we concluded that this treatment was effective. There has been no report of DAC-Tam therapy in melanoma patients on maintenance hemodialysis. Our experience suggests that DAC-Tam therapy can be applied as a treatment of melanoma patients on maintenance hemodialysis, with careful dose adjustment and monitoring of CDDP. [Skin Cancer (Japan) 2005; 20: 93-98]
